Opening a DOOR for Pivotal Studies: An Example for Complicated Urinary Tract Infections-Reference-Cited by-同舟云学术

Opening a DOOR for Pivotal Studies: An Example for Complicated Urinary Tract Infections

Published:2022-09-19 Issue:3 Volume:76 Page:e1166-e1167
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Rodríguez-Baño Jesús¹²,Gutiérrez-Gutiérrez Belén¹²^ORCID

Affiliation:

1. Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena and Departamento de Medicina, Facultad de Medicina, Universidad de Sevilla/Instituto de Biomedicina de Sevilla/CSIC , Seville , Spain

2. Centro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain

Funder

Instituto de Salud Carlos III

Innovación y Universidades

European

Development Regional Fund

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciac778/46399597/ciac778.pdf

Reference11 articles.

1. Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR);Evans;Clin Infect Dis,2015

2. Desirability of outcome ranking for the management of antimicrobial therapy (DOOR MAT): a framework for assessing antibiotic selection strategies in the presence of drug resistance;Wilson;Clin Infect Dis,2021

3. DOOR/RADAR: a gateway into the unknown?;Phillips;Clin Infect Dis,2016

4. Response adjusted for days of antibiotic risk (RADAR): evaluation of a novel method to compare strategies to optimize antibiotic use;Schweitzer;Clin Microbiol Infect,2017

5. A desirability of outcome ranking analysis of a randomized clinical trial comparing seven versus fourteen days of antibiotics for uncomplicated gram-negative bloodstream infection;Howard-Anderson;Open Forum Infect Dis,2022

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Applying Desirability of Outcome Ranking End Point to Randomized Trial of Sulopenem for the Treatment of Complicated Urinary Tract Infections;Clinical Infectious Diseases;2023-03-23